Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada

Apricus Biosciences, Inc. APRI and Stellar Pharmaceuticals Inc. SLXCF SLXCF (Pink Sheets:SLXCF), a Canadian public company, announced today the signing of an exclusive license agreement. Under the agreement, Stellar Pharma has the exclusive right to sell Apricus Bio's MycoVa™ product for the treatment of onychomycosis (nail fungus) in Canada, following receipt of Canadian regulatory approval for such product. The exclusive license agreement provides for an upfront payment, regulatory approval milestone, sales achievement milestones and royalty payments during the term of the agreement.